Tumor suppressor gene

This MedLibrary.org supplementary page on Tumor suppressor gene is provided directly from the open source Wikipedia as a service to our readers. Please see the note below on authorship of this content, as well as the Wikipedia usage guidelines. To search for other content from our encyclopedia supplement, please use the form below:

A tumor suppressor gene, or antioncogene is a gene that protects a cell from one step on the path to cancer. When this gene is mutated to cause a loss or reduction in its function, the cell can progress to cancer, usually in combination with other genetic changes.

Contents

Two-hit hypothesis

Unlike oncogenes, tumor suppressor genes generally follow the 'two-hit hypothesis', which implies that both alleles that code for a particular gene must be affected before an effect is manifested. This is due to the fact that if only one allele for the gene is damaged, the second can still produce the correct protein. In other words, mutant tumor suppressors alleles are usually recessive whereas mutant oncogene alleles are typically dominant. The two hit hypothesis was first proposed by A.G. Knudson for cases of retinoblastoma.[1] Knudson observed that the age of onset of retinoblastoma followed 2nd-order kinetics, implying that two independent genetic events were necessary. He recognized that this was consistent with a recessive mutation involving a single gene, but requiring biallelic mutation. Oncogene mutations, in contrast, generally involve a single allele because they are gain of function mutations. There are notable exceptions to the 'two hit' rule for tumors suppressors, such as certain mutations in the p53 gene product. p53 mutations can function as a 'dominant negative', meaning that a mutated p53 protein can prevent the function of normal protein from the un-mutated allele.[2] Other tumor suppressor genes which are exceptions to the 'two-hit' rule are those which exhibit haploinsufficiency. An example of this is the p27Kip1 cell cycle inhibitor, in which mutation of a single allele causes increased carcinogen susceptibility.[3]

Functions

Tumor suppressor genes, or more precisely, the proteins for which they code, either have a dampening or repressive effect on the regulation of the cell cycle or promote apoptosis, and sometimes do both. The functions of tumor suppressor proteins fall into several categories including the following:[4]

  1. Repression of genes that are essential for the continuing of the cell cycle. If these genes are not expressed, the cell cycle will not continue, effectively inhibiting cell division.
  2. Coupling the cell cycle to DNA damage. As long as there is damaged DNA in the cell, it should not divide. If the damage can be repaired, the cell cycle can continue.
  3. If the damage cannot be repaired, the cell should initiate apoptosis (programmed cell death) to remove the threat it poses for the greater good of the organism.
  4. Some proteins involved in cell adhesion prevent tumor cells from dispersing, block loss of contact inhibition, and inhibit metastasis. These proteins are known as metastasis suppressors.[5] [6]

Examples

The first tumor suppressor protein discovered was the Retinoblastoma protein (pRb) in human retinoblastoma; however, recent evidence has also implicated pRb as a tumor survival factor.

Another important tumor suppressor is the p53 tumor suppressor protein encoded by the TP53 gene. Homozygous loss of p53 is found in 70% of colon cancers, 30-50% of breast cancers and 50% of lung cancers. Mutated p53 is also involved in the pathophysiology of leukemias, lymphomas, sarcomas and neurogenic tumors. Abnormalities of the p53 gene can be inherited in Li-Fraumeni syndrome (LFS), which increases the risk of developing various types of cancers.

PTEN acts by opposing the action of PI3K, which is essential for anti-apoptotic, pro-tumorogenic Akt activation.

Other examples of tumour suppressors include APC and CD95.

See also

References

  1. ^ Knudson AG (1971). "Mutation and cancer: statistical study of retinoblastoma". Proc Natl Acad of Sci 68 (4): 820–3. doi:10.1073/pnas.68.4.820. PMID 5279523. 
  2. ^ Baker SJ, Markowitz S, Fearon ER, Willson JK, Vogelstein B. (1990). "Suppression of human colorectal carcinoma cell growth by wild-type p53.". Science 249 (4971): 912–5. doi:10.1126/science.2144057. PMID 2144057. 
  3. ^ Fero ML, Randel E, Gurley KE, Roberts JM, Kemp CJ (1998). "The murine gene p27Kip1 is haplo-insufficient for tumour suppression". Nature 396 (6707): 177–80. doi:10.1038/24179. PMID 9823898. 
  4. ^ Sherr C (2004). "Principles of tumor suppression". Cell 116 (2): 235–46. doi:10.1016/S0092-8674(03)01075-4. PMID 14744434. 
  5. ^ Yoshida, BA, Sokoloff, MM, Welch, DR, Rinker-Schaeffer CW. 2000. Metastasis-suppressor genes: a review and perspective on an emerging field. Journal of the National Cancer Institute 92: 1717-1730.
  6. ^ Hirohashi S, Kanai Y (2003). "Cell adhesion system and human cancer morphogenesis". Cancer Sci 94 (7): 575–81. doi:10.1111/j.1349-7006.2003.tb01485.x. PMID 12841864. 

External links

Wikipedia content modification information:

  • This page was last modified on 8 October 2008, at 01:12.

Wikipedia Authorship and Review

Wikipedia content provided here is not reviewed directly by MedLibrary.org. Wikipedia content is authored by an open community of volunteers and is not produced by or in any way affiliated with MedLibrary.org.

Wikipedia Usage Guidelines

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article on "Tumor suppressor gene".

The URL for this specific entry is:

All Wikipedia text is available under the terms of the GNU Free Documentation License. (See Copyrights for details). Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc.